Bernard Zinman Cm

List of Publications by Year
in descending order

263	52,610	5891 81	1314 224
papers	citations	h-index	g-index

268	268	268	26910
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 2117-2128.	13.9	8,841
2	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 311-322.	13.9	5,070
3	Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. New England Journal of Medicine, 2005, 353, 2643-2653.	13.9	4,433
4	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2019, 380, 2295-2306.	13.9	3,760
5	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 323-334.	13.9	2,809
6	Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. New England Journal of Medicine, 2006, 355, 2427-2443.	13.9	2,714
7	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 1228-1239.	13.9	1,455
8	Liraglutide and Renal Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 839-848.	13.9	903
9	Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. JAMA - Journal of the American Medical Association, 2019, 321, 69.	3.8	830
10	Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD). Diabetes Care, 2009, 32, 1224-1230.	4.3	768
11	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care, 2018, 41, 356-363.	4.3	534
12	Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes. New England Journal of Medicine, 2011, 365, 2366-2376.	13.9	507
13	Rosiglitazone-Associated Fractures in Type 2 Diabetes. Diabetes Care, 2008, 31, 845-851.	4.3	498
14	Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. New England Journal of Medicine, 2017, 377, 723-732.	13.9	480
15	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes and Endocrinology,the, 2018, 6, 105-113.	5.5	451
16	Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trialâ€"Revisited. Diabetes, 2008, 57, 995-1001.	0.3	432
17	Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2019, 322, 1155.	3.8	423
18	The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes. Annals of Internal Medicine, 2007, 146, 477.	2.0	387

#	Article	IF	Citations
19	Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2019, 140, 1693-1702.	1.6	371
20	Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality. JAMA - Journal of the American Medical Association, 2015, 313, 45.	3.8	369
21	Insulins today and beyond. Lancet, The, 2001, 358, 739-746.	6.3	353
22	Clinical Inertia in Response to Inadequate Glycemic Control: Do specialists differ from primary care physicians?. Diabetes Care, 2005, 28, 600-606.	4.3	348
23	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation, 2018, 137, 119-129.	1.6	347
24	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditorsâ€™ Expert Forum. Diabetes Care, 2018, 41, 14-31.	4.3	338
25	Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet, The, 2014, 384, 2228-2234.	6.3	336
26	SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials. Diabetes and Vascular Disease Research, 2015, 12, 90-100.	0.9	333
27	Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes. Diabetes Care, 2012, 35, 2464-2471.	4.3	305
28	Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 610-621.	5.5	301
29	Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and Microalbuminuria<subtitle>An Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort</subtitle><alt-title>Microalbuminuria Outcomes in Type 1 Diabetes</alt-title>. Archives of Internal Medicine, 2011, 171, 412.	4.3	298
30	Hyperbolic Relationship Between Insulin Secretion and Sensitivity on Oral Glucose Tolerance Test. Obesity, 2008, 16, 1901-1907.	1.5	297
31	Development and Progression of Renal Insufficiency With and Without Albuminuria in Adults With Type 1 Diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care, 2010, 33, 1536-1543.	4.3	257
32	Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes Care, 2018, 41, 2560-2569.	4.3	239
33	Overweight among children and adolescents in a Native Canadian community: prevalence and associated factors. American Journal of Clinical Nutrition, 2000, 71, 693-700.	2.2	229
34	Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2020, 141, 704-707.	1.6	225
35	Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet, The, 2010, 376, 103-111.	6.3	216
36	Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Advances and Contributions. Diabetes, 2013, 62, 3976-3986.	0.3	215

#	Article	IF	Citations
37	Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial. Diabetes Care, 2014, 37, 1480-1483.	4.3	211
38	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. Circulation, 2019, 140, 739-750.	1.6	211
39	Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 356-367.	5.5	210
40	Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation, 2019, 139, 1384-1395.	1.6	205
41	Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care, 2016, 39, 1702-1710.	4.3	200
42	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOMEÂ® trial. European Heart Journal, 2018, 39, 363-370.	1.0	199
43	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOMEâ„¢). Cardiovascular Diabetology, 2014, 13, 102.	2.7	198
44	Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA^{Â®}). Diabetes and Vascular Disease Research, 2015, 12, 164-174.	0.9	197
45	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. American Journal of Nephrology, 2017, 46, 462-472.	1.4	194
46	Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes and Endocrinology,the, 2013, 1, 28-34.	5.5	183
47	Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial. American Heart Journal, 2013, 166, 823-830.e5.	1.2	182
48	Glucoregulation During Moderate Exercise in Insulin Treated Diabetics. Journal of Clinical Endocrinology and Metabolism, 1977, 45, 641-652.	1.8	174
49	Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 134-142.	1.8	164
50	Phenotypic Characteristics of GAD Antibody-Positive Recently Diagnosed Patients With Type 2 Diabetes in North America and Europe. Diabetes, 2004, 53, 3193-3200.	0.3	154
51	Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. Journal of the American Society of Nephrology: JASN, 2018, 29, 2755-2769.	3.0	148
52	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care, 2019, 42, 2262-2271.	4.3	146
53	Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial. Diabetes Care, 2018, 41, e4-e5.	4.3	143
54	Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care, 2017, 40, 777-783.	4.3	141

#	Article	IF	Citations
55	Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes. Diabetes Care, 2015, 38, 132-139.	4.3	137
56	Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOMEÂ® trial. Diabetologia, 2018, 61, 2155-2163.	2.9	133
57	Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial. Diabetes and Vascular Disease Research, 2013, 10, 289-301.	0.9	132
58	Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. Circulation, 2018, 137, 405-407.	1.6	131
59	The Physiologic Replacement of Insulin. New England Journal of Medicine, 1989, 321, 363-370.	13.9	130
60	Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). Diabetologia, 2018, 61, 48-57.	2.9	126
61	Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation, 2019, 139, 351-361.	1.6	126
62	Prospective Associations of Vitamin D With Î²-Cell Function and Glycemia. Diabetes, 2011, 60, 2947-2953.	0.3	124
63	DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia, 2018, 61, 58-65.	2.9	124
64	Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet, The, 2011, 377, 924-931.	6.3	122
65	Common and Rare ABCA1 Variants Affecting Plasma HDL Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1983-1989.	1.1	117
66	Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. Circulation, 2018, 138, 1904-1907.	1.6	117
67	Liraglutide and the Preservation of Pancreatic Î²-Cell Function in Early Type 2 Diabetes: The LIBRA Trial. Diabetes Care, 2014, 37, 3270-3278.	4.3	115
68	Fetal Sex and Maternal Risk of Gestational Diabetes Mellitus: The Impact of Having a Boy. Diabetes Care, 2015, 38, 844-851.	4.3	112
69	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. Stroke, 2017, 48, 1218-1225.	1.0	112
70	Characterization and implications of the initial estimated glomerular filtration rate â€˜dipâ€™ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney International, 2021, 99, 750-762.	2.6	111
71	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. Journal of the American Society of Nephrology: JASN, 2020, 31, 1128-1139.	3.0	106
72	Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. Diabetes Care, 2015, 38, 793-800.	4.3	104

#	Article	IF	Citations
73	Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 834-844.	5.5	103
74	Effect of Hyperglycaemia on Arterial Pressure, Plasma Renin Activity and Renal Function in Early Diabetes. Clinical Science, 1996, 90, 189-195.	1.8	97
75	Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation, 2022, 145, 1460-1470.	1.6	97
76	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%. Circulation, 2020, 141, 407-410.	1.6	95
77	Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1969-1977.	2.2	93
78	Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. Kidney International, 2021, 99, 999-1009.	2.6	93
79	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care, 2020, 43, 1546-1552.	4.3	92
80	Each Degree of Glucose Intolerance in Pregnancy Predicts Distinct Trajectories of Î²-Cell Function, Insulin Sensitivity, and Glycemia in the First 3 Years Postpartum. Diabetes Care, 2014, 37, 3262-3269.	4.3	89
81	Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOMEÂ® randomised trial. Diabetologia, 2018, 61, 1712-1723.	2.9	88
82	Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation, 2022, 145, 575-585.	1.6	88
83	Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1705-1714.	2.2	87
84	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. American Heart Journal, 2016, 174, 103-110.	1.2	82
85	Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Circulation, 2018, 138, 2884-2894.	1.6	82
86	Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. Diabetes Care, 2018, 41, 1783-1791.	4.3	82
87	Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease. Circulation, 2018, 137, 2179-2183.	1.6	80
88	Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOMEÂ® trial. Age and Ageing, 2019, 48, 859-866.	0.7	79
89	Impact of Excessive Weight Gain on Cardiovascular Outcomes in Type 1 Diabetes: Results From the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes Care, 2017, 40, 1756-1762.	4.3	77
90	Analysis from the EMPA-REG OUTCOMEÂ® trialÂindicates empagliflozin may assist in preventingÂtheÂprogression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. Kidney International, 2019, 96, 489-504.	2.6	77

#	Article	IF	Citations
91	Renal Outcomes in Patients with Type 1 Diabetes and Macroalbuminuria. Journal of the American Society of Nephrology: JASN, 2014, 25, 2342-2350.	3.0	76
92	Paraoxonase-2 Gene (PON2) G148 Variant Associated with Elevated Fasting Plasma Glucose in Noninsulin-Dependent Diabetes Mellitus1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3373-3377.	1.8	75
93	Novel Diabetes Drugs and the Cardiovascular Specialist. Journal of the American College of Cardiology, 2017, 69, 2646-2656.	1.2	75
94	Cardiometabolic Implications of Postpartum Weight Changes in the First Year After Delivery. Diabetes Care, 2014, 37, 1998-2006.	4.3	73
95	Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINAÂ®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovascular Diabetology, 2018, 17, 39.	2.7	70
96	Association of Hematological Parameters with Insulin Resistance and Î²-Cell Dysfunction in Nondiabetic Subjects. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3824-3832.	1.8	69
97	SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. Cell Metabolism, 2019, 30, 609-613.	7.2	69
98	Sodiumâ€glucose coâ€transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol. Diabetes, Obesity and Metabolism, 2019, 21, 2192-2202.	2.2	69
99	Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPAâ€REG OUTCOME trial. European Journal of Heart Failure, 2020, 22, 126-135.	2.9	67
100	Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time?. American Journal of Medicine, 2011, 124, S19-S34.	0.6	65
101	Sex of the baby and risk of gestational diabetes mellitus in the mother: a systematic review and meta-analysis. Diabetologia, 2015, 58, 2469-2475.	2.9	62
102	Body Image Concepts Differ by Age and Sex in an Ojibway-Cree Community in Canada. Journal of Nutrition, 1996, 126, 2990-3000.	1.3	58
103	Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in) Tj ETQq1 1 0.784314 rgBT /Overl Journal, 2016, 179, 175-183.	1.2	58
104	Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucoseâ€lowering therapy?. Diabetes, Obesity and Metabolism, 2020, 22, 631-639.	2.2	58
105	Glycemic Variability in Patients With Early Type 2 Diabetes: The Impact of Improvement in Î²-Cell Function. Diabetes Care, 2014, 37, 1116-1123.	4.3	54
106	Genome-wide scanning for type 2 diabetes susceptibility in Canadian Oji-Cree, using 190 microsatellite markers. Journal of Human Genetics, 1999, 44, 10-14.	1.1	53
107	Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial. Diabetes Care, 2019, 42, 1930-1938.	4.3	52
108	Empagliflozin Reduces Myocardial Extracellular Volume in Patients WithÂType 2 Diabetes and CoronaryÂArtery Disease. JACC: Cardiovascular Imaging, 2021, 14, 1164-1173.	2.3	51

#	Article	IF	Citations
109	Effect of Rosiglitazone and Ramipril on Â-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose: The DREAM trial. Diabetes Care, 2010, 33, 608-613.	4.3	50
110	Prospective Associations of Vitamin D Status With Î²-Cell Function, Insulin Sensitivity, and Glycemia: The Impact of Parathyroid Hormone Status. Diabetes, 2014, 63, 3868-3879.	0.3	49
111	The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3702-3709.	1.8	49
112	Maternal Serum Prolactin and Prediction of Postpartum Î²-Cell Function and Risk of Prediabetes/Diabetes. Diabetes Care, 2016, 39, 1250-1258.	4.3	49
113	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). American Heart Journal, 2017, 187, 1-9.	1.2	49
114	Empagliflozin in women with type 2 diabetes and cardiovascular disease â€“ an analysis of EMPA-REG OUTCOMEÂ®. Diabetologia, 2018, 61, 1522-1527.	2.9	49
115	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. Circulation, 2019, 139, 1458-1460.	1.6	49
116	The Role of Insulin in the Metabolic Response to Exercise in Diabetic Man. Diabetes, 1979, 28, 76-81.	0.3	48
117	Predictors of sustained drug-free diabetes remission over 48â€…weeks following short-term intensive insulin therapy in early type 2 diabetes. BMJ Open Diabetes Research and Care, 2016, 4, e000270.	1.2	47
118	Determinants of reversibility of Î²-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E1398-E1407.	1.8	46
119	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPAâ€REG OUTCOME trial. ESC Heart Failure, 2021, 8, 4517-4527.	1.4	46
120	Emerging parameters of the insulin and glucose response on the oral glucose tolerance test: Reproducibility and implications for glucose homeostasis in individuals with and without diabetes. Diabetes Research and Clinical Practice, 2014, 105, 88-95.	1.1	45
121	The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care, 2020, 43, 3007-3015.	4.3	45
122	Vitamin D and Parathyroid Hormone Status in Pregnancy: Effect on Insulin Sensitivity, Î²-cell Function, and Gestational Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4506-4513.	1.8	44
123	Evaluation of Circulating Determinants of Beta-Cell Function in Women With and Without Gestational Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2683-2691.	1.8	44
124	Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. Diabetes Care, 2020, 43, 1803-1812.	4.3	44
125	A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks. Diabetes Care, 2018, 41, 1121-1124.	4.3	43
126	Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 949-959.	5.5	41

#	Article	IF	Citations
127	Longitudinal Changes in Estimated and Measured GFR in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2014, 25, 810-818.	3.0	40
128	Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes. Molecular Metabolism, 2019, 20, 63-78.	3.0	40
129	Shortâ€Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPAâ€REG OUTCOME Trial. Journal of the American Heart Association, 2020, 9, e016976.	1.6	39
130	Treatment with glucagonâ€like peptideâ€1 receptor agonists and incidence of dementia: Data from pooled doubleâ€blind randomized controlled trials and nationwide disease and prescription registers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12268.	1.8	39
131	Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. Circulation: Heart Failure, 2019, 12, e005875.	1.6	38
132	Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis. Diabetes Care, 2020, 43, 1157-1163.	4.3	38
133	Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabetes and Endocrinology,the, 2013, 1, 123-131.	5.5	37
134	Early Glomerular Hyperfiltration and Long-Term Kidney Outcomes in Type 1 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 854-861.	2.2	37
135	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 384-395.	2.2	37
136	Insulins: Past, Present, and Future. Endocrinology and Metabolism Clinics of North America, 2012, 41, 1-24.	1.2	36
137	Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies. Canadian Journal of Diabetes, 2014, 38, 364-371.	0.4	35
138	Angiotensinogen Gene Variation Associated With Variation in Blood Pressure in Aboriginal Canadians. Hypertension, 1997, 29, 1073-1077.	1.3	34
139	Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial. American Journal of Kidney Diseases, 2019, 74, 713-715.	2.1	33
140	Newer insulin analogs: advances in basal insulin replacement. Diabetes, Obesity and Metabolism, 2013, 15, 6-10.	2.2	32
141	PPARÎ³ agonists in type 2 diabetes: how far have we come in â€˜preventing the inevitableâ€™? A review of the metabolic effects of rosiglitazone. Diabetes, Obesity and Metabolism, 2001, 3, 34-43.	2.2	31
142	Effects of glucagonâ€like peptideâ€1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials. Diabetes, Obesity and Metabolism, 2020, 22, 2487-2492.	2.2	31
143	Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes. Journal of the American College of Cardiology, 2019, 73, 2780-2782.	1.2	30
144	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. American Heart Journal, 2021, 233, 141-148.	1.2	30

#	Article	IF	Citations
145	Association between uric acid levels and cardioâ€renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPAâ€REG OUTCOME. Diabetes, Obesity and Metabolism, 2020, 22, 1207-1214.	2.2	29
146	Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the <scp>EMPAâ€REG OUTCOME</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 135-141.	2.2	29
147	Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. Circulation, 2018, 138, 1599-1601.	1.6	28
148	Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOMEÂ® trial. European Heart Journal, 2020, 41, 209-217.	1.0	28
149	Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes. PLoS ONE, 2015, 10, e0141085.	1.1	28
150	Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia. Diabetes Care, 2014, 37, 1076-1082.	4.3	27
151	Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis. Canadian Journal of Diabetes, 2016, 40, 50-57.	0.4	27
152	Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial. Diabetes Care, 2019, 42, e53-e55.	4.3	27
153	Insulin and insulin analogs as antidiabetic therapy: A perspective from clinical trials. Cell Metabolism, 2021, 33, 740-747.	7.2	27
154	Rationale and design of the CAROLINAÂ® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus. BMC Neurology, 2018, 18, 7.	0.8	26
155	Changes Over Time in Glycemic Control, Insulin Sensitivity, and Â-Cell Function in Response to Low-Dose Metformin and Thiazolidinedione Combination Therapy in Patients With Impaired Glucose Tolerance. Diabetes Care, 2011, 34, 1601-1604.	4.3	25
156	Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. Circulation, 2018, 138, 1605-1607.	1.6	25
157	Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial. Diabetes Care, 2019, 42, e42-e44.	4.3	25
158	The discovery of insulin in Toronto: beginning a 100Âyear journey of research and clinical achievement. Diabetologia, 2021, 64, 947-953.	2.9	25
159	The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study: 30th Anniversary Presentations. Diabetes Care, 2014, 37, 8-8.	4.3	24
160	Bladder cancer in the EMPA-REG OUTCOME trial. Diabetologia, 2017, 60, 2534-2535.	2.9	24
161	Risk of Foot Ulcer and Lower-Extremity Amputation Among Participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care, 2022, 45, 357-364.	4.3	24
162	â^'6A Promoter variant of angiotensinogen and blood pressure variation in Canadian Oji-Cree. Journal of Human Genetics, 1998, 43, 37-41.	1.1	23

#	Article	IF	Citations
163	Genetic variation in paraoxonaseâ€2 is associated with variation in plasma lipoproteins in Canadian Ojiâ€Cree. Clinical Genetics, 1998, 54, 394-399.	1.0	23
164	Liraglutide and Glycaemic Outcomes in the LEADER Trial. Diabetes Therapy, 2018, 9, 2383-2392.	1.2	23
165	Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. American Journal of Hypertension, 2020, 33, 1092-1101.	1.0	23
166	Use of diuretics and outcomes in patients with type 2 diabetes: findings from the <scp>EMPAâ€REG OUTCOME</scp> trial. European Journal of Heart Failure, 2021, 23, 1085-1093.	2.9	23
167	Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. Diabetes, Obesity and Metabolism, 2019, 21, 1745-1751.	2.2	22
168	Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the <scp>EMPAâ€REG OUTCOME</scp> trial. Diabetes, Obesity and Metabolism, 2020, 22, 2335-2347.	2.2	22
169	Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3025-3035.	1.8	22
170	The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. Nephrology Dialysis Transplantation, 2020, 35, 895-897.	0.4	22
171	Twoâ€year trial of intermittent insulin therapy vs metformin for the preservation of Î²â€cell function after initial shortâ€term intensive insulin induction in early type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 1399-1407.	2.2	20
172	Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPAâ€REG OUTCOME trial. Diabetes, Obesity and Metabolism, 2020, 22, 1141-1150.	2.2	20
173	Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study. Diabetologia, 2021, 64, 1235-1245.	2.9	20
174	HbA1c, Insulin Resistance, and Î²-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy. Diabetes Care, 2019, 42, e1-e3.	4.3	19
175	Clinical inertiaâ€”a barrier to effective management of T2DM. Nature Reviews Endocrinology, 2013, 9, 635-636.	4.3	18
176	Electrocardiographic Abnormalities and Cardiovascular Disease Risk in Type 1 Diabetes: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care, 2017, 40, 793-799.	4.3	18
177	Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). Diabetes, Obesity and Metabolism, 2019, 21, 1625-1633.	2.2	18
178	Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11). Diabetes Therapy, 2020, 11, 53-70.	1.2	18
179	Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. Journal of the American Society of Echocardiography, 2020, 33, 644-646.	1.2	18
180	Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidaseâ€4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized <scp>CAROLINA</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 569-580.	2.2	18

#	Article	IF	Citations
181	Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the <scp>EMPAâ€REG OUTCOME</scp> trial with a focus on Asia. Diabetes, Obesity and Metabolism, 2021, 23, 1886-1891.	2.2	18
182	Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. Cardiovascular Diabetology, 2019, 18, 156.	2.7	17
183	Oxidative stress and endothelial dysfunction are associated with reduced cognition in type 2 diabetes. Diabetes and Vascular Disease Research, 2019, 16, 577-581.	0.9	17
184	Delayed timing of post-challenge peak blood glucose predicts declining beta cell function and worsening glucose tolerance over time: insight from the first year postpartum. Diabetologia, 2015, 58, 1354-1362.	2.9	16
185	The Relationship Between Parathyroid Hormone and 25-Hydroxyvitamin D During and After Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1729-1736.	1.8	16
186	Adipose Tissue Insulin Resistance Is Longitudinally Associated With Adipose Tissue Dysfunction, Circulating Lipids, and Dysglycemia: The PROMISE Cohort. Diabetes Care, 2021, 44, 1682-1691.	4.3	16
187	Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPAâ€REG OUTCOME trial. ESC Heart Failure, 2021, 8, 2603-2607.	1.4	16
188	Efficacy and Safety of Linagliptin Co-Administered with Low-Dose Metformin Once Daily Versus High-Dose Metformin Twice Daily in Treatment-NaÃ¯ve Patients with Type 2 Diabetes: a Double-Blind Randomized Trial. Advances in Therapy, 2015, 32, 201-215.	1.3	15
189	Effect of Short-term Intensive Insulin Therapy on Post-challenge Hyperglucagonemia in Early Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2987-2995.	1.8	15
190	Dayâ€toâ€day fasting selfâ€monitored blood glucose variability is associated with risk of hypoglycaemia in insulinâ€treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials. Diabetes, Obesity and Metabolism, 2019, 21, 622-630.	2.2	15
191	Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. Journal of Hypertension, 2020, 38, 1829-1840.	0.3	15
192	Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. Diabetes, Obesity and Metabolism, 2022, 24, 1061-1071.	2.2	15
193	Determinants of longitudinal change in insulin clearance: the Prospective Metabolism and Islet Cell Evaluation cohort. BMJ Open Diabetes Research and Care, 2019, 7, e000825.	1.2	14
194	Early benefits of empagliflozin in patients with or without heart failure: findings from EMPAâ€REG OUTCOME. ESC Heart Failure, 2020, 7, 3401-3407.	1.4	14
195	Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis. Metabolism Open, 2020, 7, 100039.	1.4	14
196	LEADER-4. Journal of Hypertension, 2016, 34, 1140-1150.	0.3	13
197	Chronic liraglutide therapy induces an enhanced endogenous glucagonâ€like peptideâ€1 secretory response in early type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 744-748.	2.2	13
198	Effect of chronic liraglutide therapy and its withdrawal on time to postchallenge peak glucose in type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2018, 314, E287-E295.	1.8	13

#	Article	IF	Citations
199	Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). Diabetes, Obesity and Metabolism, 2019, 21, 1437-1444.	2.2	13
200	Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial. Cardiovascular Diabetology, 2020, 19, 200.	2.7	13
201	Liraglutide and semaglutide: Pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes. Alzheimer's and Dementia, 2020, 16, e042909.	0.4	13
202	Associations of circulating 25(OH)D with cardiometabolic disorders underlying type 2 diabetes mellitus in an Aboriginal Canadian community. Diabetes Research and Clinical Practice, 2015, 109, 440-449.	1.1	12
203	Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?. Canadian Journal of Diabetes, 2017, 41, 6-9.	0.4	12
204	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the <scp>EMPAâ€REG OUTCOME</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 2775-2784.	2.2	12
205	The ongoing evolution of basal insulin therapy over 100â€‰years and its promise for the future. Diabetes, Obesity and Metabolism, 2022, 24, 17-26.	2.2	12
206	Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3003-e3007.	1.8	12
207	The ADD1 G460W polymorphism is not associated with variation in blood pressure in Canadian Oji-Cree. Journal of Human Genetics, 1999, 44, 225-229.	1.1	11
208	Fasting Capillary Glucose as a Screening Test for Ruling Out Gestational Diabetes Mellitus. Journal of Obstetrics and Gynaecology Canada, 2013, 35, 515-522.	0.3	11
209	Longitudinal Associations of Phospholipid and Cholesteryl Ester Fatty Acids With Disorders Underlying Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2536-2544.	1.8	11
210	Diabetes Research and Care Through the Ages. Diabetes Care, 2017, 40, 1302-1313.	4.3	11
211	Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 clinical trials. Diabetes, Obesity and Metabolism, 2020, 22, 2193-2198.	2.2	11
212	Impact of polyvascular disease with and without coâ€existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of <scp>EMPAâ€REG OUTCOME</scp>. Diabetes, Obesity and Metabolism, 2021, 23, 1173-1181.	2.2	11
213	Determinants of Small for Gestational Age in Women With Type 2 Diabetes in Pregnancy: Who Should Receive Metformin?. Diabetes Care, 2022, 45, 1532-1539.	4.3	10
214	Biomarkers of tubulointerstitial damage and function in type 1 diabetes. BMJ Open Diabetes Research and Care, 2017, 5, e000461.	1.2	9
215	The Macrophage Activation Marker Soluble CD163 is Longitudinally Associated With Insulin Sensitivity and Î²-cell Function. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e285-e294.	1.8	9
216	Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME^{Â®}. Diabetes and Vascular Disease Research, 2020, 17, 147916412097525.	0.9	9

#	Article	IF	Citations
217	Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPAâ€REG OUTCOME Trial. Journal of the American Heart Association, 2021, 10, e020053.	1.6	9
218	Traditional foods and 25(OH)D concentrations in a subarctic First Nations community. International Journal of Circumpolar Health, 2016, 75, 31956.	0.5	8
219	Longâ€term efficacy and safety of combined insulin and glucagonâ€like peptideâ€1 therapy: Evidence from the LEADER trial. Diabetes, Obesity and Metabolism, 2019, 21, 2450-2458.	2.2	8
220	Can the cardiovascular risk reductions observed with empagliflozin in the EMPAâ€REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. Diabetes, Obesity and Metabolism, 2020, 22, 1151-1156.	2.2	8
221	Shortâ€term intensive insulin as induction and maintenance therapy for the preservation of betaâ€cell function in early type 2 diabetes (<scp>RESETâ€IT Main</scp>): A 2â€year randomized controlled trial. Diabetes, Obesity and Metabolism, 2021, 23, 1926-1935.	2.2	8
222	Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes. JACC: Heart Failure, 2021, 9, 568-577.	1.9	8
223	Clusters of fatty acids in the serum triacylglyceride fraction associate with the disorders of type 2 diabetes. Journal of Lipid Research, 2018, 59, 1751-1762.	2.0	7
224	Predictors and Clinical Implications of a False Negative Glucose Challenge Test in Pregnancy. Journal of Obstetrics and Gynaecology Canada, 2013, 35, 889-898.	0.3	6
225	Steno-2 â€" a small study with a big heart. Nature Reviews Endocrinology, 2016, 12, 692-694.	4.3	6
226	Screening Glucose Challenge Test in Pregnancy Can Identify Women With an Adverse Postpartum Cardiovascular Risk Factor Profile: Implications for Cardiovascular Risk Reduction. Journal of the American Heart Association, 2019, 8, e014231.	1.6	6
227	Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12). Diabetes and Vascular Disease Research, 2020, 17, 147916412097093.	0.9	6
228	Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. CKJ: Clinical Kidney Journal, 2021, 14, 226-236.	1.4	6
229	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the <scp>CREDENCE</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1652-1659.	2.2	6
230	Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes. EClinicalMedicine, 2022, 43, 101240.	3.2	6
231	Progress in reducing vascular complications of diabetes. Nature Reviews Endocrinology, 2014, 10, 451-453.	4.3	5
232	Asymmetric dimethylarginine and arginine metabolites in women with and without a history of gestational diabetes. Journal of Diabetes and Its Complications, 2017, 31, 964-970.	1.2	5
233	Serum Ferritin and Glucose Homeostasis in Women With Recent Gestational Diabetes. Canadian Journal of Diabetes, 2019, 43, 567-572.	0.4	5
234	The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. Diabetes and Metabolism, 2022, 48, 101331.	1.4	5

#	Article	IF	Citations
235	Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease. Diabetes Research and Clinical Practice, 2022, 186, 109837.	1.1	5
236	Delivery by Caesarean Section and Infant Cardiometabolic Status at One Year of Age. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 864-869.	0.3	4
237	The Distribution of Fatty Acid Biomarkers of Dairy Intake across Serum Lipid Fractions: The Prospective Metabolism and Islet Cell Evaluation (PROMISE) Cohort. Lipids, 2019, 54, 617-627.	0.7	4
238	FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) â€“ A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	4
239	Erythropoietin and glucose homeostasis in women at varying degrees of future diabetic risk. Journal of Diabetes and Its Complications, 2015, 29, 26-31.	1.2	3
240	Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms. Physiology, 2018, 33, 197-210.	1.6	3
241	Intermittent Intensive Insulin Therapy for Type 2 Diabetes: Effects on Hypoglycemia, Weight Gain, and Quality of Life Over 2 Years. Endocrine Practice, 2019, 25, 899-907.	1.1	3
242	Shortâ€term costâ€utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). Diabetes, Obesity and Metabolism, 2019, 21, 1706-1714.	2.2	3
243	Comment on Miller and Orchard: Understanding Metabolic Memory: A Tale of Two Studies. Diabetes 2020;69:291â€“299. Diabetes, 2020, 69, e7-e8.	0.3	3
244	The pharmokinetics of insulin analogues and pumps. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2001, 18, S3-S4.	0.2	2
245	Oscar B. Crofford: Clinician, Scientist, Educator, Advocate for People With Diabetes, and Godfather of Diabetes Control and Complications Trial. Diabetes Care, 2014, 37, 3139-3142.	4.3	2
246	Response to Comment on Lachin et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care 2017;40:777â€“783. Diabetes Care, 2017, 40, e165-e166.	4.3	2
247	Efficacy and Safety of Inhaled Insulin Therapy. Annals of Internal Medicine, 2006, 144, 533.	2.0	2
248	The clinical challenges of managing type 2 diabetes and the potential of GLPâ€1â€based therapies. Diabetes, Obesity and Metabolism, 2009, 11, 1-3.	2.2	1
249	Response to Comment on Kramer et al. Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia. Diabetes Care 2014;37:1076â€“1082. Diabetes Care, 2014, 37, e209-e209.	4.3	1
250	Cardiovascular Outcome Trials in Diabetes: Will the EMPA-REG OUTCOME and LEADER Trials Influence Clinical Decisions in Type 2 Diabetes?. Canadian Journal of Diabetes, 2016, 40, 379-381.	0.4	1
251	Response by Wanner et al to Letters Regarding Article, â€œEmpagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Diseaseâ€• Circulation, 2018, 138, 850-851.	1.6	1
252	LB005KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE â€˜EGFR DIPâ€™ IN EMPA-REG OUTCOME. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	1

#	Article	IF	Citations
253	131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. Diabetes, 2020, 69, 131-LB.	0.3	1
254	Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. Diabetes Care, 2022, 45, 585-593.	4.3	1
255	Does an intensive multifactorial intervention reduce mortality in type 2 diabetes mellitus?. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 434-435.	2.9	0
256	Response to Comment on Kramer et al. Glucagon Response to Oral Glucose Challenge in Type 1 Diabetes: Lack of Impact of Euglycemia. Diabetes Care 2014;37:1076â€“1082. Diabetes Care, 2014, 37, e225-e225.	4.3	0
257	Response to Comment on Retnakaran et al. Liraglutide and the Preservation of Pancreatic Î²-Cell Function in Early Type 2 Diabetes: The LIBRA Trial. Diabetes Care 2014;37:3270â€“3278. Diabetes Care, 2015, 38, e26-e26.	4.3	0
258	Treatment of Type 1 Diabetes Mellitus in Adults. , 2016, , 770-787.e4.		0
259	Response by Zinman et al to Letter Regarding Article, â€œEmpagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Riskâ€• Stroke, 2017, 48, e256-e257.	1.0	0
260	SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOMEÂ® TRIAL. Nephrology Dialysis Transplantation, 2018, 33, i487-i487.	0.4	0
261	The authors reply. Kidney International, 2020, 97, 213-214.	2.6	0
262	PPARgamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone. Diabetes, Obesity and Metabolism, 2001, 3 Suppl 1, 34-43.	2.2	0
263	Effects of empagliflozin on uric acid levels and gout: observations from the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0